- The Short Answer: What CBG Stands For
- The Field Behind the Acronym
- Who Certifies CBG and What the Blueprint Covers
- The Fifteen Content Categories at a Glance
- The Heavy-Weighted Categories
- The Laboratory Category: Where Biochemistry Meets Practice
- Who Works in Clinical Biochemical Genetics
- Sequencing Your Preparation Around the Blueprint
- Exam Timing and What Is Not Published
- Frequently Asked Questions
- CBG means Clinical Biochemical Genetics, the ABMGG specialty focused on inborn errors of metabolism and their laboratory diagnosis.
- The ABMGG blueprint organizes the exam into fifteen content categories, led by Amino acids at about 15%.
- Lipids (13%), Organic acids (12%), and Lysosomes (12%) together carry roughly a third of the blueprint.
- The next CBG exam is identified for August 2027, since biochemical specialties are offered in odd years.
The Short Answer: What CBG Stands For
On this site, CBG stands for Clinical Biochemical Genetics. It refers to the medical genetics subspecialty concerned with inherited disorders of metabolism: conditions in which a defective enzyme, transporter, or cofactor pathway disrupts the body's normal chemistry. Phenylketonuria, urea cycle defects, fatty acid oxidation disorders, lysosomal storage diseases, and mitochondrial disorders all fall under this umbrella.
The acronym is shared by unrelated terms in other fields, so context matters. When a clinical laboratory director, a metabolic geneticist, or a fellowship program says "CBG," they are talking about the biochemical genetics discipline certified through the American Board of Medical Genetics and Genomics (ABMGG). Nothing in this article refers to any other credential or concept that happens to abbreviate the same way.
If you want a quick orientation to the credential itself, our companion pages on what CBG is and what CBG stands for cover the basics. This article goes one level deeper: it explains what the phrase means in practice and what the content behind it looks like.
The Field Behind the Acronym
Clinical biochemical genetics sits at the intersection of clinical medicine, analytical chemistry, and molecular genetics. The central question is deceptively simple: is a patient's metabolism working the way it should, and if not, which step is broken?
Practitioners answer that question using biochemical evidence such as amino acid profiles, organic acid patterns, acylcarnitine profiles, enzyme assays, and metabolite markers, and then connect those findings to genes, inheritance patterns, and treatment. Newborn screening programs, metabolic clinics, and reference laboratories all depend on this skill set.
Who Certifies CBG and What the Blueprint Covers
The certifying body is the American Board of Medical Genetics and Genomics (ABMGG). The current source document for exam content is the ABMGG Biochemical Genetics Blueprint and Content Codes, effective August 2025. That blueprint lists the content topics candidates are expected to know and assigns each category an approximate percentage.
Two details are worth understanding before you plan anything:
- The percentages are approximate. The fifteen published figures (15, 12, 7, 10, 13, 12, 7, 3, 3, 3, 1, 2, 3, 8, and 3 percent) sum to 102%, reflecting a discrepancy in the source. Treat them as relative emphasis, not a precise count of questions.
- The blueprint is an objectives list, not a curriculum. It tells you what topics can appear. It does not replace textbooks, case-based learning, or hands-on laboratory and clinical experience.
For eligibility and prerequisites, see our CBG requirements guide, and for a domain-by-domain walkthrough, the complete guide to all 15 CBG content areas.
The Fifteen Content Categories at a Glance
The table below reproduces the blueprint's categories and approximate weights exactly as published.
| Category | Approx. Weight | Representative Topics |
|---|---|---|
| Amino acids | 15% | PKU, tyrosinemias, MSUD, homocystinuria, urea cycle defects |
| Organic acids | 12% | Propionic and methylmalonic acidemia, IVA, glutaric acidemia type I |
| Cofactors | 7% | Cobalamin, biotin, molybdenum, folate, pyridoxine, biopterin |
| Carbohydrates | 10% | Glycogenoses, galactose and fructose disorders, congenital disorders of glycosylation |
| Lipids | 13% | Fatty acid oxidation disorders, hyperlipidemias, cholesterol disorders |
| Lysosomes | 12% | Mucopolysaccharidoses, sphingolipidoses, Pompe, cystinosis, NCL |
| Mitochondria | 7% | Electron transport chain defects, mtDNA disorders, MELAS, Leigh syndrome |
| Peroxisomes | 3% | Zellweger spectrum, X-linked adrenoleukodystrophy |
| Purines and pyrimidines | 3% | Lesch-Nyhan, ADA deficiency, UMP synthase deficiency |
| Transport | 3% | Cystinuria, lysinuric protein intolerance, carnitine and glucose transport |
| Creatine | 1% | Creatine metabolism disorders |
| Neurotransmitters | 2% | SSADH deficiency, dopamine synthesis disorders, GABA metabolism |
| Metals | 3% | Wilson disease, Menkes disease, iron, zinc |
| Laboratory | 8% | QA/QC, artifact, techniques, regulations |
| Other disease category | 3% | Conditions outside the named categories |
Notice how the structure mirrors the way metabolic disease is organized in practice: by the class of molecule or organelle involved. That is part of what the phrase "biochemical genetics" signals, since the field's taxonomy follows the chemistry.
The Heavy-Weighted Categories
Four categories account for roughly half of the blueprint's emphasis: Amino acids (15%), Lipids (13%), Organic acids (12%), and Lysosomes (12%). Here is what each one demands.
Amino acids (about 15%)
The largest category rewards candidates who can move fluidly between pathway, enzyme, metabolite, and clinical picture.
- PKU and hyperphenylalaninemia, including the link to biopterin pathways
- Tyrosinemias and glycine encephalopathy/hyperglycinemia
- MSUD and other disorders of branched-chain amino acids
- Homocystinuria, sulfur amino acid disorders, and re-methylation defects
- Urea cycle defects and the serine-related disorders grouped under "Other"
Lipids (about 13%)
This category spans energy metabolism and structural lipid biology.
- Fatty acid oxidation disorders at the short-chain, medium-chain, and long-chain levels, plus multiple acyl-CoA dehydrogenase deficiency (GA2)
- Hyperlipidemias, including Tangier disease
- Cholesterol metabolism disorders such as Smith-Lemli-Opitz and Niemann-Pick C, along with bile acid disorders
Organic acids (about 12%)
Pattern recognition drives this category: given a urine organic acid profile or an acylcarnitine finding, which block explains it?
- Methylmalonic acidemia (excluding cobalamin defects) and propionic acidemia
- 3-MCC deficiency and other C5OH-related disorders; IVA and other C5-related disorders
- Glutaric acidemia type I and ketone body disorders such as HMG-CoA lyase and SCOT deficiency
- Glutathione synthetase deficiency, ECHS1, and non-type 1 3-methylglutaconic aciduria
Lysosomes (about 12%)
Expect enzyme-defect logic, substrate accumulation, and the clinical phenotypes that follow.
- Mucopolysaccharidoses, including Types I, II, III, IV, VI, and VII
- Sphingolipidoses: Gaucher, Fabry, GM2 gangliosidoses (Tay-Sachs, Sandhoff), Krabbe, Niemann-Pick A and B, GM1 gangliosidosis
- Multiple enzyme deficiencies such as ML-II, ML-III, and multiple sulfatase deficiency
- Pompe disease, cystinosis, and NCL
The Laboratory Category: Where Biochemistry Meets Practice
At about 8%, the Laboratory category is the most distinctive feature of this exam compared with a purely clinical genetics assessment. It covers QA/QC, artifact, techniques, and regulations, meaning the analytical side of the specialty.
Why does this matter for the meaning of "clinical biochemical genetics"? Because the discipline is as much about producing reliable laboratory data as interpreting it. A candidate who cannot recognize an artifact in a metabolite profile, or who is shaky on the quality systems that govern clinical testing, may misread an otherwise textbook case. Questions in this area test judgment: is this result real, is it an artifact of collection or medication, and what does regulation require of the laboratory?
Key Takeaway
Do not treat the Laboratory category as filler. At roughly 8%, it outweighs the combined weight of Peroxisomes, Purines and pyrimidines, and Transport (each about 3%). Dedicate real study time to analytical techniques and quality principles.
Who Works in Clinical Biochemical Genetics
The training and certification pathway leads to a recognizable set of employers and roles:
- Academic medical centers with metabolic genetics clinics, where specialists diagnose and manage inborn errors of metabolism.
- Clinical reference and hospital laboratories that run biochemical genetics testing, including amino acid, organic acid, and acylcarnitine analysis.
- Newborn screening programs, which depend on expertise in interpreting screening abnormalities and guiding confirmatory testing.
- Children's hospitals managing patients with metabolic crises, dietary therapy, and enzyme replacement.
- Industry and research settings involved in diagnostics and therapeutic development for rare metabolic disease.
For more on career outcomes, see our pages on CBG jobs and the ROI analysis of CBG certification. We deliberately avoid quoting salary figures here, since no verified numbers are supplied for this credential; the CBG salary guide discusses the topic qualitatively.
Sequencing Your Preparation Around the Blueprint
General study technique is not the point of this article, but the blueprint itself suggests a sensible order. A sequence that respects how the categories build on one another might look like this:
Core small-molecule metabolism
- Amino acids first: it is the largest category and teaches the pathway-to-phenotype logic everything else relies on.
- Follow with Organic acids, since many organic acidemias are downstream of amino acid catabolism.
Cofactors and energy metabolism
- Cofactors (cobalamin, biotin, biopterin) explain why some amino acid and organic acid disorders respond to vitamin therapy.
- Then Lipids and Carbohydrates, centered on fatty acid oxidation, glycogenoses, and galactose/fructose disorders.
Organelle-based disease
- Lysosomes, Mitochondria, and Peroxisomes, grouped by where the biochemistry happens.
Smaller categories and the laboratory
- Purines and pyrimidines, Transport, Creatine, Neurotransmitters, Metals, and Other disease category.
- Finish with the Laboratory category, so QA/QC and artifact recognition are fresh going into review.
For a fuller plan, read the CBG study guide, and keep the CBG cheat sheet nearby for rapid review. When you are ready to test recall, the CBG practice tests let you drill the categories above under exam-style conditions.
Exam Timing and What Is Not Published
According to ABMGG announcements, the biochemical specialties are offered in odd-numbered years, and the next CBG exam is identified for August 2027. ABMGG has also approved a transition toward an annual certifying examination schedule, so confirm current scheduling directly with the board before you commit to a timeline. Our CBG exam dates page tracks the details.
Several practical specifics are not established in the official source material available to us, so we do not state them here: the exact number of questions, the time limit, the registration fee, and the passing score. Rather than guess, we recommend checking the ABMGG website directly. Related topics are discussed qualitatively in our articles on certification cost, passing score, and pass rate, and on exam difficulty.
Frequently Asked Questions
On this site, CBG means Clinical Biochemical Genetics, the medical genetics specialty focused on diagnosing and managing inherited metabolic disorders through biochemical and genetic analysis. It is certified through the American Board of Medical Genetics and Genomics (ABMGG).
No. Clinical biochemical genetics is a focused discipline within the broader field, emphasizing metabolic disease and laboratory-based diagnosis. Its blueprint includes categories such as Amino acids, Organic acids, Lipids, and a dedicated Laboratory category.
According to the ABMGG blueprint effective August 2025, Amino acids is largest at about 15%, followed by Lipids at 13%, Organic acids at 12%, and Lysosomes at 12%. The percentages are approximate and total 102% due to a source discrepancy.
The next CBG exam is identified as August 2027, since biochemical specialties are offered in odd years. ABMGG has also approved a move toward an annual certifying schedule, so verify current dates with the board.
Start with our overview of CBG certification and the explainer on what CBG certification is, then review the official ABMGG blueprint to see the exact content categories.